Big picture - Why invest in Genedrive PLC
Genedrive PLC Snapshot
The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc. With its historical founding in the provision of contract research services to Pharmaceutical and Biotech companies, the business was renamed genedrive plc in July 2016. The name reflects the new direction of the company targeting molecular diagnostic requirements at the point of need, with shareholder expectations being directed at the superior returns offered by the Genedrive® business model.
The company operates under three active Divisions.
The Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based tests via a 'razor/razor blade' business model across an increasing range of applications. The instrument's development has been significantly de-risked through a range of varied applications and external independent validations.
Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid patient diagnostics.
The Epistem Pharmacogenomics Division specialises in providing gene expression and DNA genotyping information utilising knowledge developed working with epithelial stem cells and obtaining gene expression information from tiny amounts of starting material. The Pharmacogenomics Division has evolved to capitalise on this proprietary knowledge, providing innovative services and developing pioneering products. The Division provides GCLP accredited gene expression and genotype analysis for drug development and diagnostic programs. The unique combination of in-house expertise and proprietary knowledge ensures that the Division is a preferred partner of choice for pharmaceutical and biotechnology companies worldwide.
Contract Research Services
The Epistem Contract Research Services Division is committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline. Underpinned by world-renowned knowledge of epithelial stem cell biology, Contract Research Services provide comprehensive integrated service packages across key therapeutic areas. The Division continues to develop innovative and clinically relevant assays and models, collaborating with commercial partners, participating in grant applications and supporting government initiatives.
The Genedrive molecular diagnostics division is developing and commercialising its low cost versatile, simple to use and robust point-of-need or point-of-care Genedrive® diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform MTB/RIF test has been launched in India and a Genedrive® HCV test has been successfully assessed by Institute Pasteur, Paris.
The Company's Pharmacogenomics Division trades as Epistem and specialises in providing gene expression and DNA genotyping information utilising knowledge developed working with epithelial stem cells and obtaining gene expression information from small amounts of starting material. The Pharmacogenomics Division has evolved to capitalise on this proprietary knowledge, providing innovative services and developing pioneering products. The Division provides GCLP accredited gene expression and genotype analysis for drug development and diagnostic programs. The unique combination of in-house expertise and proprietary knowledge ensures Epistem's Personalised Medicine Service is a preferred partner of choice for pharmaceutical and biotechnology companies worldwide.
Contract Research Services
The Company's Contract Research Services Division trade as Epistem and is committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline. Underpinned by world-renowned knowledge of epithelial stem cell biology, Contract Research Services provides comprehensive integrated service packages across key therapeutic areas. The Division continues to develop innovative and clinically relevant assays and models, collaborating with commercial partners, participating in grant applications and supporting government initiatives. The Epistem Contract Research Services Division strives to be a leader in the field of pre-clinical testing.
Utilising the Epistem scientific heritage and expertise in epithelial stem cells, the Novel Therapies Division aims to identify key regulators of epithelial stem cell regulators and develop novel therapeutics targeting this mechanism. Following successful industry collaborations, the Epistem Novel Therapies Division retains a portfolio of assets relating to the discovery and development of epithelial stem cell regulators, with implications in both oncology and regenerative medicine.
Ian Gilham - Ph.D., Non-Executive Chairman
Ian was appointed a Director on 24 November 2014 and as Non-Executive Chairman on 11 May 2015. He is currently Non-Executive Chairman of three life sciences companies including AIM-quoted Horizon Discovery Group Plc, which provides gene-editing tools to support translational genomics and the development of personalised medicine, Multiplicom NV focussed on the development and commercialisation of next generation DNA sequencing products and Biosurfit SA, focussed on development and commercialisation of point-of-care diagnostic products. Dr Gilham was formerly Chief Executive Officer of Axis-Shield Plc.
David Budd - Chief Executive Officer
David was appointed a Director and Chief Executive on March 1, 2016. He has over 20 years of international commercial and operational experience in the diagnostics and medical devices field. He previously served as General Manager of Leica Biosystems Amsterdam and Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, product development, and commercial launches for diagnostic tests. Prior to Leica, David’s roles included Point-of-Care, molecular, and central laboratory marketing and commercialisation responsibilities at Siemens Healthcare Diagnostics, Bayer Diagnostics, and Visible Genetics.
Matthew Fowler - Chief Financial Officer
Matthew was appointed Chief Financial Officer on December 13th 2016. He has over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes. Prior to that, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.
Catherine Booth - Ph.D., Managing Director, Contract Research Services
Catherine is a co-founder of Epistem, now genedrive plc, and prior to starting Epistem she worked for 10 years with Prof. Chris Potten at the Paterson Institute. Whilst at the Paterson Institute she developed many preclinical assays. This knowledge is at the core of the Contract Research Service. Catherine received her Ph.D. from the Emmanuel College, University of Cambridge.
Allan Brown - Ph.D., Chief Operating Officer, Diagnostics Division
Allan was appointed to the Board on 1st February, 2014. During a seventeen year period with Tepnel Life Sciences plc, latterly as Divisional Managing Director, Allan's management roles covered product development, commercial product launch, BD and M&A. Allan left Tepnel in 2010 to join Qiagen N.V. in Manchester, and managed the final development and launch of the company's first US FDA approved products, helping secure the site as QIAGEN's Global Centre of Excellence for molecular diagnostic product development.
Roger Lloyd - Ph.D., Non-Executive Director
Trained as a biochemist, Roger has almost 35 years' experience in the healthcare and biotechnology sector, particularly in the areas of strategic planning and business development. International business management with ICI Plc and AstraZeneca Plc. As Executive Director of Global Licensing at AstraZeneca, he personally completed 24 transactions, including strategic alliances with Abgenix and CAT, and acquisitions of KuDOS Pharmaceuticals and CAT. He operates as a Board Adviser in the biotech sector.
Robert Nolan - Ph.D., Non-Executive Director
Robert has been a Non-Executive Director of the Company since 2004. He brings with him a wealth of expertise in partnering and licensing negotiations with both small biotechnology and large pharmaceutical companies. Prior to his retirement he was Director, Global Licensing at AstraZeneca. He is also a non-executive Director of Phico Therapeutics Ltd.
Identity and percentage holding of significant shareholders
|Directors and related shareholders|
|Hugh John Joseph Rylands||375,076||2.01%|
|Total Directors' holdings||1,524,895||8.16%|
|Dr B Cobb||491,228||2.63%|
|Remaining shares in public hands||16,673,323||89.21%|
|Total shares in issue||18,689,446||100.00%|
|Odey Asset Management||2,398,254||12.83%|
|River and Mercantile Asset Management||1,055,000||5.64%|
|Amati Global Investors||781,250||4.18%|
48 Grafton Street
Tel: +44 (0)161 989 0245
Fax: +44 (0)161 989 0262
Email: [email protected]
48 Grafton Street
Manchester M3 9XX
Natwest Commercial Banking
5th Floor, 1 Spinningfields Square
Manchester M3 3AP
Nominated Advisor and Broker
Peel Hunt LLP
120 London Wall
Neville Registrars Limited
18 Laurel Lane
101 Barbirolli Square
Lower Mosley Street
Manchester M2 3PW
Covington & Burling LLP
London WC2R 1BH
Financial PR and Communications
Consilium Strategic Communications